Compare Abeona Therapeutics Inc (ABEO) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Workiva Inc — how do they compare? Abeona Therapeutics Inc trades at $7.5 (market cap $421.19M), while Workiva Inc trades at $67.87 (market cap $3.76B). The key difference: Workiva Inc is far larger — about 8.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | WK | |
|---|---|---|
Market Cap | $421.19M | $3.76B |
Sector | Health | Technology |
52-Week High | $7.45 | $93.31 |
52-Week Low | $4.17 | $44.31 |
Enterprise Value | $276.10M | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Workiva (WK) trades at $67.62, up 0.45% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth accelerating to 19% in Q2 2026. Technical indicators signal bullish momentum despite overbought RSI conditions, while fundamentals reflect improving profitability with net income margin turning positive to 4.87% in 2026.
Outlook remains positive with 89% analyst buy ratings and $69 consensus target offering 2% upside. Key opportunities include AI product expansion and sustained subscription growth, while risks involve high valuation multiples (P/E 82.2) and competitive pressures in regulatory software. The stock's proximity to 52-week highs suggests momentum but warrants caution on pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
